Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Treatment for Recurrent Glioblastoma
NCT05432518Phase 1Enrolling by invitation
- Sponsor
- American Health Staffing Group
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afatinib, dasatinib, palbociclib, everolimus and olaparib in glioblastoma (GBM), sponsored by American Health Staffing Group. Primary endpoint: Success rate of personalized GBM treatment at 24 months. Started Jun 2023; status: enrolling by invitation.
02
Drugs
afatinibdasatinibpalbociclibeverolimusolaparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05432518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432518.